Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06065540 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,734
- Enrollment target
- 20
- Study locations
NCT06065540 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Novo Nordisk A/S. The registered enrollment target is 2,734 participants, roughly in line with the 2,726-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target. The trial reports 20 study locations across 4 states.
The verdict
NCT06065540, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,734 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Cagrilintide
- DRUG Placebo cagrilintide
- DRUG Placebo semaglutide
Study Locations (20)
California
- Velocity Clinical Res-Banning - Banning
- Velocity Clin Res-Chula Vista - Chula Vista
- John Muir Physicians Network - Concord
- Headlands Research California, LLC - Escondido
- Velocity Clin Res Gardena - Gardena
- Velocity Clin Res San Diego - La Mesa
- Loma Linda Univ Hlth Cr Endo - Loma Linda
- Facey Medical Foundation - Mission Hills
- Desert Oasis Hlthcr Med Group - Palm Springs
- Desert Oasis Hlthcr Med Group - Palm Springs
- Velocity Clin Res- San Bern - San Bernardino
- Linda Vista Health Care Ctr - San Diego
- Velocity Clin Res Santa Ana - Santa Ana
- Premier Medical Center, Inc. - Toluca Lake
Alabama
- Synexus Clin Res-Birmingham - Birmingham
- Univ of Alabama_Birmingham - Birmingham
- Cahaba Research - Pelham
Arizona
- Velocity Clinical Research-Phoenix - Phoenix
- Synexus Rsch /Cnt Phnx Med C - Phoenix
Arkansas
- Arkansas Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,734 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2026-01-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06065540
The ClinicalTrials.gov registry entry for NCT06065540 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,734 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 2,726-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.
NCT06065540 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06065540 about?
NCT06065540 is a clinical study titled "A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor". The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone....
What is the current status of trial NCT06065540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,734 participants. The study started on 2023-09-27. Estimated completion is 2026-01-06.
What conditions does trial NCT06065540 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT06065540?
The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).
Who is sponsoring clinical trial NCT06065540?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06065540 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
-
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.